Weill Cornell Medical College, New York, New York 10021, USA.
J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S13-20. doi: 10.6004/jnccn.2010.0112.
Venous thromboembolism (VTE), osteonecrosis of the jaw, renal failure, and anemia are all common complications of multiple myeloma therapy. Many of these adverse events have been documented only in the past 5 to 10 years, in conjunction with the introduction of a series of the newer therapies thalidomide, bortezomib, and lenalidomide. This article discusses these complications in detail and provides strategies for health care providers to best prevent, identify, and manage them. Preventive measures, such as VTE prophylaxis and appropriate dental hygiene, as well as patient education, dose adjustments, limited duration of drug treatment, and consideration of therapies that are associated with less burdensome adverse-event profiles, can contribute to substantially improved outcomes and quality of life.
静脉血栓栓塞症（VTE）、下颌骨坏死、肾衰竭和贫血都是多发性骨髓瘤治疗的常见并发症。其中许多不良事件仅在过去 5 到 10 年内，随着一系列新型疗法沙利度胺、硼替佐米和来那度胺的引入才被记录下来。本文详细讨论了这些并发症，并为医疗保健提供者提供了最佳预防、识别和管理这些并发症的策略。预防措施，如 VTE 预防和适当的口腔卫生，以及患者教育、剂量调整、药物治疗的有限持续时间，以及考虑与负担较小的不良事件谱相关的治疗方法，都可以显著改善预后和生活质量。
